VERAPAMIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Verapamil Hydrochloride, and what generic alternatives are available?
Verapamil Hydrochloride is a drug marketed by Mylan, Rising, Abraxis Pharm, Bedford, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Heritage, Hospira, Intl Medication, Luitpold, Mankind Pharma, Marsam Pharms Llc, Smith And Nephew, Solopak, Zydus Pharms, Amneal, Caplin, Exela Pharma, Micro Labs, Nephron, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Pliva, Strides Pharma, Sun Pharm Inds Inc, Actavis Elizabeth, Chartwell Rx, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, and Watson Labs. and is included in sixty-five NDAs.
The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Verapamil Hydrochloride
A generic version of VERAPAMIL HYDROCHLORIDE was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VERAPAMIL HYDROCHLORIDE?
- What are the global sales for VERAPAMIL HYDROCHLORIDE?
- What is Average Wholesale Price for VERAPAMIL HYDROCHLORIDE?
Summary for VERAPAMIL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 36 |
| NDAs: | 65 |
| Finished Product Suppliers / Packagers: | 43 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 150 |
| Patent Applications: | 2,869 |
| What excipients (inactive ingredients) are in VERAPAMIL HYDROCHLORIDE? | VERAPAMIL HYDROCHLORIDE excipients list |
| DailyMed Link: | VERAPAMIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for VERAPAMIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| EpiEndo Pharmaceuticals | Phase 1 |
| CTC Clinical Trial Consultants AB | Phase 1 |
| Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
Pharmacology for VERAPAMIL HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for VERAPAMIL HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for VERAPAMIL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 100 mg and 200 mg | 020943 | 1 | 2006-07-20 |
| VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 300 mg | 020943 | 1 | 2006-05-19 |
US Patents and Regulatory Information for VERAPAMIL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heritage | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET;ORAL | 071881-001 | Apr 5, 1988 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Somerset | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 211035-002 | Jun 18, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 070738-001 | May 6, 1987 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET;ORAL | 072924-001 | Jun 29, 1993 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
